Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 12/2009

01-12-2009 | Hepatobiliary Tumors

Long-Term Results of Hepatic Resection Combined with Intraoperative Local Ablation Therapy for Patients with Multinodular Hepatocellular Carcinomas

Authors: Shinji Itoh, MD, PhD, Kazutoyo Morita, MD, Shigeru Ueda, MD, Keishi Sugimachi, MD, PhD, Yo-ichi Yamashita, MD, PhD, Tomonobu Gion, MD, PhD, Kengo Fukuzawa, MD, PhD, Kenzo Wakasugi, MD, PhD, Akinobu Taketomi, MD, PhD, Yoshihiko Maehara, MD, PhD, FACS

Published in: Annals of Surgical Oncology | Issue 12/2009

Login to get access

Abstract

Background

Recently, local ablation therapy has been widely used for treatment of small hepatocellular carcinoma (HCC). The present study assessed the outcome of hepatic resection combined with intraoperative local ablation therapy in patients with multinodular HCCs.

Methods

Forty-one patients with initial and multinodular HCCs underwent hepatic resection combined with intraoperative local ablation therapy. The mean maximum diameter of all tumors was 3.8 cm (range 2.1–16.0 cm), and the mean number of nodules was 3.2 (range 2–11). We evaluated the survival rates and assessed the prognostic factors associated with overall survival rates using Cox proportional hazard models.

Results

Intraoperative local ablation therapy was completed in all patients with no evidence of residual viable tumor on the first postoperative computed tomography (CT) scan. The 3-, 5- and 7-year overall survival rates were 84.3%, 61.2%, and 61.2%, respectively. Patients with preoperative des-gamma carboxyprothrombin (DCP) level >300 mAU/ml showed significantly worse overall survival than those with DCP level ≤300 mAU/ml (P < 0.01).

Conclusions

Hepatic resection combined with intraoperative local ablation therapy is effective for multinodular HCCs. DCP >300 mAU/ml was a significant prognostic factor of long-term overall survival.
Literature
1.
Shimada M, Takenaka K, Fujiwara Y, et al. Risk factors linked to postoperative morbidity in patients with hepatocellular carcinoma. Br J Surg. 1998;85:195–8.CrossRefPubMed
2.
Taketomi A, Kitagawa D, Itoh S, et al. Trends in morbidity and mortality after hepatic resection for hepatocellular carcinoma: an institute’s experience with 625 patients. J Am Coll Surg. 2007;204(4): 580–7.CrossRefPubMed
3.
Takenaka K, Kawahara N, Yamamoto K, et al. Results of 280 liver resections for hepatocellular carcinoma. Arch Surg. 1996;131:71–6.PubMed
4.
Yamashita Y-i, Taketomi A, Itoh S, et al. Longterm favorable results of limited hepatic resections for patients with hepatocellular carcinoma. J Am Coll Surg. 2007;205(1):19–26.CrossRefPubMed
5.
Liver Cancer Study Group of Japan. Primary liver cancers in Japan. Cancer. 1980;45:2663–9.CrossRef
6.
Lai EC, Fan ST, Lo CM, et al. Hepatic resection for hepatocellular carcinoma: an audit of 343 patients. Ann Surg. 1995;221:291–8.CrossRefPubMed
7.
Todo S, Furukawa H. Living donor liver transplantation for adult patients with hepatocellular carcinoma. Experience in Japan. Ann Surg. 2004;240:451–61.CrossRefPubMed
8.
Taketomi A, Soejima Y, Yoshizumi T, et al. Liver transplantation for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg. 2008;15:124–30.CrossRefPubMed
9.
Kudo M. Local ablation therapy for hepatocellular carcinoma: current status and future prospectives. J Gastroenterol. 2004;39(3): 205–14.CrossRefPubMed
10.
Sala M, Llovet JM, Vilana R, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology. 2004:40: 1352–60.CrossRefPubMed
11.
Coinaud C. Lobes et segments hepatiques. Press Med. 1954;62: 709–12.
12.
Shimada M, Takenaka K, Taguchi K, et al. Prognostic factors after repeat hepatectomy for recurrent hepatocellular carcinoma. Ann Surg. 1998;227:80–5.CrossRefPubMed
13.
Kanematsu T, Furuta T, Takenaka K, et al. A 5-year experience of lipiodolization: selective regional chemotherapy for 200 patients with hepatocellular carcinoma. Hepatology. 1989;10:98–102.CrossRefPubMed
14.
Itoh S, Taketomi A, Tanaka S, et al. Role of growth factor receptor-bound protein 7 in hepatocellular carcinoma. Mol Cancer Res. 2007;5:667–73.CrossRefPubMed
15.
Mazzafero V, Regalia E, Doci R, et al. Liver transplantation for treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;14:728.
16.
Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954;7:462–503.CrossRefPubMed
17.
Itoh S, Maeda T, Shimada M, et al. Role of expression of focal adhesion kinase in progression of hepatocellular carcinoma. Clin Cancer Res. 2004;10:2812–7.CrossRefPubMed
18.
Tateishi R, Shiina S, Teratani T, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer. 2005;103:1201–9.CrossRefPubMed
19.
Seki T, Wakabayashi M, Nakagawa T, et al. Percutaneous microwave coagulation therapy for patients with small hepatocellular carcinoma: comparison with percutaneous ethanol injection therapy. Cancer. 1999;85:1694–702.CrossRefPubMed
20.
Santambrogio R, Opocher E, Costa M, et al. Survival and intra-hepatic recurrences after laparoscopic radiofrequency of hepatocellular carcinoma in patients with cirrhosis. J Surg Oncol. 2005;89:218–25.CrossRefPubMed
21.
Kawamoto C, Ido K, Isoda N, et al. Long-term outcomes for patients with solitary hepatocellular carcinoma treated by laparoscopic microwave coagulation. Cancer. 2005;103:985–93.CrossRefPubMed
22.
Raut CP, Izzo F, Marra P, et al. Significant long-term survival after radiofrequency ablation of unresectable hepatocellular carcinoma in patients with cirrhosis. Ann Surg Oncol. 2005;12:616–28.CrossRefPubMed
23.
Choi D, Lim HK, Joh JW, et al. Combined hepatectomy and radiofrequency ablation for multifocal hepatocellular carcinomas: long-term follow-up results and prognostic factors. Ann Surg Oncol. 2007;14:3510–8.CrossRefPubMed
24.
Fong Y, Sun RL, Jarnagin W, et al. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg. 1999;229:790–800.CrossRefPubMed
25.
Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-size hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology. 2000;32:1224–9.CrossRefPubMed
26.
Livraghi T, Bolondi L, Buscarini L, et al. No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. Italian Cooperative HCC Study Group. J Hepatol. 1995;22:522–6.CrossRefPubMed
27.
Urata K, Matsumata T, Kamakura T, et al. Lipiodolization for unresectable hepatocellular carcinoma: An analysis of 205 patients using univariate and multivariate analysis. J Surg Oncol. 1994;56:54–8.CrossRefPubMed
28.
The Liver Cancer Study Group of Japan. The general rules for clinical and pathological study of primary liver cancer, 4th ed. Tokyo: Kanehara; 2000.
29.
Vivarelli M, Guglielmi A, Ruzzenente A, et al. Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. Ann Surg. 2004;240:102–7.CrossRefPubMed
30.
Wakai T, Shirai Y, Suda T, et al. Long-term outcomes of hepatectomy vs percutaneous ablation for treatment of hepatocellular carcinoma ≤4 cm. World J Gastroenterol. 2006;12:546–52.PubMed
31.
Makuuchi M, Hasegawa H, Yamazaki S, et al. The use of operative ultrasound as an aid to liver resection in patients with hepatocellular carcinoma. World J Surg. 1987;11:615–21.CrossRefPubMed
32.
Scaife CL, Ng CS, Ellis LM, et al. Accuracy of preoperative imaging of hepatic tumors with helical computed tomography. Ann Surg Oncol. 2006;13:542–6.CrossRefPubMed
33.
The Liver Cancer Study Group of Japan. Predictive factors for long-term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. Cancer. 1994;74:2772–80.CrossRef
34.
Shimada M, Yamashita Y, Hamatsu T, et al. The role of des-gamma-carboxy prothrombin levels in hepatocellular carcinoma and liver tissues. Cancer Lett. 2000;159:87–94.CrossRefPubMed
35.
Marrero JA, SuGL, Wei W, et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology. 2003;37:1114–21.CrossRefPubMed
36.
Shimada M, Takenaka K, Fujiwara Y, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein positive status as a new prognostic indicator after hepatic resection for hepatocellular carcinoma. Cancer. 1996;78:2094–100.CrossRefPubMed
37.
Shirabe K, Itoh S, Yoshizumi T, et al. The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin. J Surg Oncol. 2007;95:235–40.CrossRefPubMed
38.
Koike Y, Shiratori Y, Sato S, et al. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer. 2001;91:561–9.CrossRefPubMed
39.
Soejima Y, Taketomi A, Yoshizumi T, et al. Extended indication for living donor liver transplantation in patients with hepatocellular carcinoma. Transplantation. 2007;83:893–9.CrossRefPubMed
40.
Taketomi A, Sanefuji K, Soejima Y et al. Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation. 2009;87:531–7.CrossRefPubMed
41.
Ito T, Takada Y, Ueda M, et al. Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. Liver Transpl. 2007;13:1637–44.CrossRefPubMed
Metadata
Title
Long-Term Results of Hepatic Resection Combined with Intraoperative Local Ablation Therapy for Patients with Multinodular Hepatocellular Carcinomas
Authors
Shinji Itoh, MD, PhD
Kazutoyo Morita, MD
Shigeru Ueda, MD
Keishi Sugimachi, MD, PhD
Yo-ichi Yamashita, MD, PhD
Tomonobu Gion, MD, PhD
Kengo Fukuzawa, MD, PhD
Kenzo Wakasugi, MD, PhD
Akinobu Taketomi, MD, PhD
Yoshihiko Maehara, MD, PhD, FACS
Publication date
01-12-2009
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 12/2009
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0721-0

Other articles of this Issue 12/2009

Annals of Surgical Oncology 12/2009 Go to the issue

Healthcare Policy and Outcomes

Outcome of Low-Volume Surgery for Esophageal Cancer in a High-Volume Referral Center

Gynecologic Oncology

Modified Radical Hysterectomy Versus Extrafascial Hysterectomy in the Treatment of Stage I Endometrial Cancer: Results From the ILIADE Randomized Study

Breast Oncology

The Role of Lymph Node Metastasis in the Systemic Dissemination of Breast Cancer

Gastrointestinal Oncology

Esophagogastric Junction Adenocarcinoma According to Siewert Classification in Taiwan

Translational Research and Biomarkers

IMP3 Is a Novel Prognostic Marker that Correlates with Colon Cancer Progression and Pathogenesis

Pancreatic Tumors

Resectable Pancreatic Cancer: Who Really Benefits From Resection?